Rapastinel, also known by its developmental code as GLYX-13, is a novel compound primarily investigated for its potential therapeutic effects in treating mood disorders, particularly depression. It is classified as a glycine-site NMDA receptor modulator, which means it interacts with the N-methyl-D-aspartate (NMDA) receptor, a critical component in synaptic plasticity and memory function. Rapastinel is notable for its rapid onset of action and favorable side effect profile compared to traditional antidepressants. It is administered via intravenous infusion and has been studied for its ability to enhance synaptic connectivity and promote neuroplasticity. The compound has shown promise in clinical trials, demonstrating efficacy in alleviating depressive symptoms without the typical side effects associated with conventional antidepressants, such as weight gain or sexual dysfunction. Additionally, its unique mechanism of action distinguishes it from other NMDA receptor antagonists, making it a subject of interest in ongoing research for various neuropsychiatric conditions.

Rapastinel

117928-94-6: Rapastinel, also known by its developmental code as GLYX-13, is a novel compound primarily investigated for its potential therapeutic effects in treating mood disorders, particularly depression. It is classified as a glycine-site NMDA receptor modulator, which means it interacts with the N-methyl-D-aspartate (NMDA) receptor, a critical component in synaptic plasticity and memory function. Rapastinel is notable for its rapid onset of action and favorable side effect profile compared to traditional antidepressants. It is administered via intravenous infusion and has been studied for its ability to enhance synaptic connectivity and promote neuroplasticity. The compound has shown promise in clinical trials, demonstrating efficacy in alleviating depressive symptoms without the typical side effects associated with conventional antidepressants, such as weight gain or sexual dysfunction. Additionally, its unique mechanism of action distinguishes it from other NMDA receptor antagonists, making it a subject of interest in ongoing research for various neuropsychiatric conditions.

GLYX 13

GLYX-13 trifluoroacetate

Rapastinel (TPPT-amide) (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator.

CAS 117928-94-6

Rapastinel

GLYX 13

Ref: IN-DA008TPG

Rapastinel

Ref: 54-BUP00335

GLYX-13 trifluoroacetate

Ref: 7W-GK9893

Rapastinel

Ref: TM-T3407